Transdermal Oxybutynin

  title={Transdermal Oxybutynin},
  author={Claudine M. Baldwin and Gillian M. Keating},
Abstract▴ Oxybutynin inhibits contraction of the detrusor muscle in the overactive bladder by binding to muscarinic M3 receptors and blocking acetylcholinergic activation.▴ The transdermal oxybutynin system, applied twice weekly, delivers continuous oxybutynin over a 96-hour patch wear period. The transdermal route of administration avoids the extensive first-pass metabolism of oxybutynin to its active metabolite, N- desethyloxybutynin.▴ In two well designed trials in patients with overactive… 

Insights into the Management of Overactive Bladder with Transdermal Oxybutynin: A Practical Review

Evidence available of the use of OXY-TDS in the management of patients with OAB is focused on to help clinicians in the challenges involved in the treatment options for patients with this condition.

Botulinum Toxin A’s Expanding Role in the Management of Pediatric Lower Urinary Tract Dysfunction

Botulinum toxin A’s utility in the pediatric population is evolving, and is currently being used in the treatment of lower urinary tract dysfunction, both in children with neuropathic compromise, and non-neuropathic overactive bladders.

Management of Mixed Urinary Incontinence

Treatment includes lifestyle changes, behavioral therapies, medication and nerve modulation, and future therapies may include new medications adapting potassium and calcium channels and more widespread use of sacral neuromodulation.

Management of urinary incontinence.

The authors report that they have no financial, commercial, or industrial relationships in regard to this article.

Bladder Outlet Obstruction and Overactive Bladder in Males



Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability.

Despite the occurrence of unwanted anticholinergic effects in many patients, and apparent lack of efficacy in the elderly institutionalised population, oxybutynin should be considered for the drug of first choice in patients with detrusor overactivity, including the elderly ambulatory population, when pharmacological therapy is indicated.

Management of overactive bladder with transdermal oxybutynin.

Transdermal oxybutynin (OXY-TDS) has shown comparable efficacy and improved tolerability when compared with conventional pharmacotherapy, and has unique dermatologic skin application site reactions, including erythema and pruritus.

Advantages for Transdermal over Oral Oxybutynin to Treat Overactive Bladder: Muscarinic Receptor Binding, Plasma Drug Concentration, and Salivary Secretion

The present study has shown that transdermal oxy butynin binds significantly to rat bladder muscarinic receptors without producing both long-lasting occupation of exocrine receptors and cessation of cholinergic salivation evoked by oral oxybutynin.

Transdermal oxybutynin in the treatment of adults with overactive bladder: combined results of two randomized clinical trials

Transdermal oxybutynin was shown to be efficacious, with a proven safety profile, and may be utilized for patients with overactive bladder as a treatment option that could enhance compliance.

Transdermal oxybutynin for overactive bladder.

Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence.

Impact of Transdermal Oxybutynin on Work Productivity in Patients with Overactive Bladder

OAB contributes to decreased work productivity due to job interruptions as well as fatigue and may result in productivity improvement when patients receive 3.9 mg/day via twice weekly patch application for up to 6 months with OXY-TDS treatment.

Pharmacokinetics of the R- and S-Enantiomers of Oxybutynin and N-Desethyloxybutynin Following Oral and Transdermal Administration of the Racemate in Healthy Volunteers

The differences between R-OXY and R-DEO following the two routes of administration support the potential for comparable clinical efficacy and reduced anticholinergic side-effects with transdermal treatment.